A Phase IB Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 [semaxanib] and Paclitaxel in Recurrent or Metastatic Carcinoma of the Head and Neck
Phase of Trial: Phase I
Latest Information Update: 02 Mar 2010
At a glance
- Drugs Semaxanib (Primary) ; Paclitaxel
- Indications Head and neck cancer
- Focus Adverse reactions
- 11 Jun 2007 Updated from NCT record dated 4 Jun 2007.
- 11 Jan 2007 Status change
- 08 Sep 2005 New trial record.